CN103561776B - 放射性标记的谷氨酰胺酰环化酶抑制剂 - Google Patents

放射性标记的谷氨酰胺酰环化酶抑制剂 Download PDF

Info

Publication number
CN103561776B
CN103561776B CN201280025603.6A CN201280025603A CN103561776B CN 103561776 B CN103561776 B CN 103561776B CN 201280025603 A CN201280025603 A CN 201280025603A CN 103561776 B CN103561776 B CN 103561776B
Authority
CN
China
Prior art keywords
alkyl
compound
acid
detection
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201280025603.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN103561776A (zh
Inventor
U·海泽
D·拉姆斯贝克
H-U·德穆特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vivoryon Therapeutics AG
Original Assignee
Probiodrug AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Probiodrug AG filed Critical Probiodrug AG
Publication of CN103561776A publication Critical patent/CN103561776A/zh
Application granted granted Critical
Publication of CN103561776B publication Critical patent/CN103561776B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0453—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Radiology & Medical Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
CN201280025603.6A 2011-05-27 2012-05-24 放射性标记的谷氨酰胺酰环化酶抑制剂 Expired - Fee Related CN103561776B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161490654P 2011-05-27 2011-05-27
US61/490,654 2011-05-27
PCT/EP2012/059649 WO2012163773A1 (en) 2011-05-27 2012-05-24 Radiolabelled glutaminyl cyclase inhibitors

Publications (2)

Publication Number Publication Date
CN103561776A CN103561776A (zh) 2014-02-05
CN103561776B true CN103561776B (zh) 2016-08-31

Family

ID=46149465

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201280025603.6A Expired - Fee Related CN103561776B (zh) 2011-05-27 2012-05-24 放射性标记的谷氨酰胺酰环化酶抑制剂

Country Status (14)

Country Link
US (2) US8945510B2 (enExample)
EP (1) EP2714098A1 (enExample)
JP (1) JP2014515364A (enExample)
KR (1) KR20140028076A (enExample)
CN (1) CN103561776B (enExample)
AU (1) AU2012264951A1 (enExample)
BR (1) BR112013030341A2 (enExample)
CA (1) CA2835014A1 (enExample)
EA (1) EA028533B1 (enExample)
IL (1) IL229187A (enExample)
MX (1) MX2013013946A (enExample)
SG (2) SG194770A1 (enExample)
WO (1) WO2012163773A1 (enExample)
ZA (1) ZA201308329B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014140279A1 (en) 2013-03-15 2014-09-18 Probiodrug Ag Novel inhibitors
CN104230778B (zh) * 2014-07-14 2017-01-04 大连大学 β-烃氧酰基-γ-烃基-N-烃基-γ-丁内酰胺的合成方法
SG11201700777VA (en) 2014-08-04 2017-02-27 Nuevolution As Optionally fused heterocyclyl-substituted derivatives of pyrimidine useful for the treatment of inflammatory, metabolic, oncologic and autoimmune diseases
US10513515B2 (en) 2017-08-25 2019-12-24 Biotheryx, Inc. Ether compounds and uses thereof
EP3830093A1 (en) 2018-07-27 2021-06-09 Biotheryx, Inc. Bifunctional compounds as cdk modulators
KR102230832B1 (ko) * 2019-06-17 2021-03-24 (주) 메디프론디비티 N-치환된 티오우레아 또는 우레아 유도체 및 이를 유효성분으로 함유하는 글루타미닐 사이클레이즈 활성 관련 질환의 예방 또는 치료용 약학적 조성물
EP4076657A1 (en) 2019-12-20 2022-10-26 Nuevolution A/S Compounds active towards nuclear receptors
EP4076661A1 (en) 2019-12-20 2022-10-26 Nuevolution A/S Compounds active towards nuclear receptors
WO2021198955A1 (en) 2020-03-31 2021-10-07 Nuevolution A/S Compounds active towards nuclear receptors
EP4126875A1 (en) 2020-03-31 2023-02-08 Nuevolution A/S Compounds active towards nuclear receptors
US11897930B2 (en) 2020-04-28 2024-02-13 Anwita Biosciences, Inc. Interleukin-2 polypeptides and fusion proteins thereof, and their pharmaceutical compositions and therapeutic applications

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110092501A1 (en) * 2009-09-11 2011-04-21 Probiodrug Ag Novel inhibitors

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT712759A (enExample) 1963-01-09
US5304367A (en) * 1990-11-16 1994-04-19 New York University In vivo brain imaging agent and method for diagnosis of psychiatric disorders
US7732162B2 (en) * 2003-05-05 2010-06-08 Probiodrug Ag Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases
KR101099206B1 (ko) * 2004-02-05 2011-12-27 프로비오드룩 아게 신규한 글루타미닐 시클라제 저해제
US8703096B2 (en) 2006-04-21 2014-04-22 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Beta-amyloid PET imaging agents
WO2008055945A1 (en) * 2006-11-09 2008-05-15 Probiodrug Ag 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcer, cancer and other diseases
NZ590658A (en) * 2008-07-31 2012-07-27 Probiodrug Ag Glutaminyl cyclase as a diagnostic / prognostic indicator for neurodegenerative diseases
EP2344157B1 (en) 2008-09-04 2016-05-25 Probiodrug AG Novel inhibitors
EP2411057B1 (en) 2009-03-23 2020-05-06 Eli Lilly and Company Imaging agents for detecting neurological disorders
CA2789440C (en) 2010-03-10 2020-03-24 Probiodrug Ag Heterocyclic inhibitors of glutaminyl cyclase (qc, ec 2.3.2.5)

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110092501A1 (en) * 2009-09-11 2011-04-21 Probiodrug Ag Novel inhibitors

Also Published As

Publication number Publication date
JP2014515364A (ja) 2014-06-30
BR112013030341A2 (pt) 2016-11-29
CN103561776A (zh) 2014-02-05
US9610368B2 (en) 2017-04-04
CA2835014A1 (en) 2012-12-06
US8945510B2 (en) 2015-02-03
EA201301334A1 (ru) 2014-05-30
SG10201604304RA (en) 2016-07-28
MX2013013946A (es) 2014-01-31
IL229187A0 (en) 2013-12-31
ZA201308329B (en) 2015-02-25
SG194770A1 (en) 2013-12-30
KR20140028076A (ko) 2014-03-07
IL229187A (en) 2017-04-30
US20120301398A1 (en) 2012-11-29
WO2012163773A1 (en) 2012-12-06
EA028533B1 (ru) 2017-11-30
NZ617581A (en) 2016-03-31
US20150104389A1 (en) 2015-04-16
EP2714098A1 (en) 2014-04-09
AU2012264951A1 (en) 2013-12-12

Similar Documents

Publication Publication Date Title
CN103561776B (zh) 放射性标记的谷氨酰胺酰环化酶抑制剂
EP2501696B1 (en) Imaging agents and their use for the diagnostic in vivo of neurodegenerative diseases, notably alzheimer's disease and derivative diseases
RU2376282C2 (ru) Стереоселективный синтез аминокислот для получения изображения опухоли
AU2012304359B2 (en) Compositions, methods, and systems for the synthesis and use of imaging agents
AU2019264073B2 (en) 2-amino-2-(1,2,3-triazole-4-yl)propane-1,3-diol derivative of novel compound for directly inhibiting ASM activity, and use thereof
HUP0302956A2 (hu) Tioflavinszármazékok az Alzheimer-kór antemortem diagnózisában történő alkalmazásra, eljárás a vegyületek előállítására és ezeket tartalmazó gyógyszerkészítmények
KR20250016195A (ko) 전립선-특이적 막 항원(psma) 리간드
TW201023900A (en) Radioisotope-labeled lysine and ornithine derivatives, their use and processes for their preparation
HK1194301A (en) Radiolabelled glutaminyl cyclase inhibitors
HK1194301B (en) Radiolabelled glutaminyl cyclase inhibitors
Watanabe et al. Novel radiogallium-labeled pyridyl benzofuran derivative for detection of amylin aggregates in pancreas
WO2013040183A1 (en) Beta-amyloid imaging agents, methods of manufacture, and methods of use thereof
SagsttaS'Transversa Heiser et al.(43) Pub. Date: Nov. 29, 2012
KR20250011145A (ko) 개선된 신장 청소율을 갖는 전립선-특이적 막 항원(psma) 리간드
EP3845541A1 (en) Radioactive imidazothiadiazole derivative compound
NZ617581B2 (en) Radiolabelled glutaminyl cyclase inhibitors
WO2025225738A1 (ja) がん治療用医薬組成物
JP6591431B2 (ja) 侵害受容処理並びに記憶障害及び認知異常の病態生理学的研究におけるプローブとして高度に選択的なシグマ受容体リガンド及び放射性リガンド
JP2021102593A (ja) タウを画像化する新規化合物
JP2020023455A (ja) モノアミンオキシダーゼｂイメージングプローブ
HK1200030B (en) Compositions, methods, and systems for the synthesis and use of imaging agents
WO2011124713A1 (en) Labelled huprine derivatives and their use in medical imaging

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1194301

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1194301

Country of ref document: HK

CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20160831

Termination date: 20170524

CF01 Termination of patent right due to non-payment of annual fee